All the chemicals were purchased from commercial sources and used without further purification. Mono-methyl fumarate, tert-butyl bromoacetate, N,N-diisopropylethylamine where the gradient was 5% B to 95% B in 15 min at a flow rate of 1 ml/min. All the synthetic steps were further characterized using LCMS (Shimadzu 2020 UFLC-MS, Japan) with an YMC-Triart C18 (5 μm, 4.6 × 150 mm) column for their respective masses. NMR spectra ( 1 H NMR, 13 C NMR, HMBC and HSQC) were recorded on a Bruker AVANCE III 400 MHz
spectrometer using deuterated methanol as the solvent. HRMS was carried out on a Bruker microTOF-QII.
Peptide synthesis:
The model peptide YGGF was synthesized using Fmoc chemistry in solid phase at 0.1 mmol scale. Amino acids were dissolved in 1.0 ml of DMF along with HATU and DIPEA followed by addition to the resin. The ratio of Fmoc protected amino acid to free amine was 2:1 and each coupling was carried out for 1hr. A ratio of 1:1:2 of amino acid: HATU: DIPEA was employed in the synthesis. Fmoc deprotection was performed in 4.0 ml of 20% piperdine in DMF for 5 minutes twice. In all the steps the resin was washed with approx. 5.0 ml of DMF (2 x), DCM (2 x) and DMF (2 x) consecutively. An aliquot of the synthesized peptide was cleaved from the resin and monitored by HPLC as well as LCMS.
4-Methoxy-4-oxo-3-(1,4,7-triazonan-1-yl)butanoic acid (1):
1,4,7-triazacyclononane (991.5 mg, 2.0 equiv.) and DIPEA (1.33 ml, 2.0 equiv.) were dissolved in 10 ml DCM. To this solution, 500 mg (1.0 equiv.) of Mono-methyl fumarate pre dissolved in 1.0 ml DCM was added drop-wise over a period of 10-15 min. After 2 hr of agitation, the DCM was removed in vacuo. The product was further dissolved in 4.0 ml DMF and kept overnight at -20 o C for the precipitation of the (1). The DMF was decanted and the residual DMF was co-evaporated with toluene in vacuo which gave a yield of 94%. 
3-(4,7-Bis(((9H-fluoren-9-yl)methoxy)carbonyl)-1,4,7-triazonan-1-yl)-4-methoxy-4-oxobutanoic acid (2):
Compound 1 (100 mg, 1.0 equiv.) and NaHCO 3 (162 mg, 5 equiv.) was dissolved in 60 ml of water and acetone (1:1). The mixture was cooled down to 0 o C and 286 mg (2.2 equiv.) of Fmoc-OSu pre-dissolved in 2.0 ml acetone was added dropwise over a period of 10-15 min followed by overnight stirring. The reaction was then concentrated in vacuo and extracted with diethyl ether to remove the unreacted Fmoc-OSu. Thereafter, the resulting reaction mixture was acidified with 10 ml 1M HCl followed by extraction of the compound with 50 ml diethyl ether. The organic layer was evaporated in vacuo to give a white solid yielding 82%. LCMS (positive mode) showed desired m/z 704. The product was then used for the next step without further purification. consecutively. An aliquot of the synthesized peptide was cleaved from the resin and monitored by analytical HPLC as well as LCMS. LCMS (positive mode) showed desired m/z 683.
Tert-butyl 2,2'-(7-(18-amino-17-benzyl-8-(4-hydroxybenzyl)-3,6,9,12,15,18-hexaoxo-2-oxa-7,10,13,16-tetraazaoctadecan-4-yl)-1,4,7-triazonane-1,4-diyl)diacetate on resin (4):
Compound (3); 0.0125 mmol was swelled with 1 ml DCM for 5 min followed by filtration, to which tert-butyl bromoacetate (5.5 µl, 3.0 equiv.) and DIPEA (6.5 µl, 3.0 equiv. ) in 0.4 ml of NMP was added and the reaction mixture left to stir for 2.5 hr 1 . The resin was washed with approx. 5.0 ml of DMF (2x) and DCM (2x) consecutively. An aliquot of the synthesized compound was cleaved from the resin and monitored by analytical HPLC. LCMS (positive mode) showed its desired m/z 799. hydroxybenzyl)-1,4,7,10,13-pentaoxo-3,6,9 ,12-tetraazahexadecan-16-oic acid (5):
1-amino-2-benzyl-15-(4,7-bis(2-tert-butoxy-2-oxoethyl)-1,4,7-triazonan-1-yl)-11-(4-
The functionalized peptide on resin (4); 0.0125 mmol was swelled in 1.0 ml DCM for 5 min followed by filtration, and 1.0 ml of 1M LiOH (dissolved in methanol and THF in 1:1 ratio) was added. The reaction was carried out for a period of 30 min at room temperature. The 
Conjugation of cold Ga to NODASA-Peptide:
Cold Ga was labelled to NODASA peptide as described before by Peter A. Knetsch et. al 2 .
1.0 mg of NODASA-peptide (6) was dissolved in 828 µl of water; 167 µl 
Transchelation assay:
The stability of 69 Ga NODAGA complexation was carried out by the EDTA challenge as described by previous researchers 3 . 69 Ga [NODASA]-peptide was incubated with 500 fold excess of EDTA at room temperature. Samples were tested for transchelation at six different time points i.e. 0 min, 30 min, 60 min, 120 min, 180 min and 240 min respectively and monitored using Q-TOF LCMS.
